Member Info for FPTP

What will Bungey be stying on the AJB Investor evening? It's a great inevestment ???

Makes the options look even more egregious.

Managemnt need to hold out as this will be much higher in two years time - depends if Tosca want to cash in early or let business get to a higher Mc before selling.

I think it is right that MW has gone, I think RB needs to go as well, clearly the forecasts were over optimistic by two years? Now is the time to get a new team on board to drive this forward and re-align the performance targets and benefits to ensure all stakeholders are being fairly rewarded.

In the previous Calvine report they were forecasting EPS of 86.81p in 2026, in this report this has moved out two years as they are forecasting EPS of 87.2 in 2028.

Don't forget to add the directors significantly de-risked their buy with 2.7M options each at £0.53.

There was no mention of the share price crash, or for that matter why losing out on sales in Scotland causes such a dent to the finances (NB no mumber was mentioned) - they must have been forecasting very aggressively.
CFO said that there were effectively three options which they would review in due course:
Debt (with warrants)
Giving a higher share of an asset to a partner for an upfront payment, and
A placing
All ways shareholders lose, especially so if the SP lingers at these levels.

Management costs high; management hubris high.
Failure to get Efmody approved by SMC means missing their cash forecash hence this needs addressing to cover the high costs. Six months ago they stated that there was sufficient cash to take the cortisol deficiency franchise through to profitability, clearly that is no longer the picture.
They have already flagged that they will need additional funding to progress their non cortisol deficiency prospects.

Ed C - we do not know each other, lets keep it that way. If you don't like what I sayyour call. Meanwhile the SP is minus 66% YOY, XBI minus 30% so I am not allowed to call that out?

Do you not read the company published information:
https://www.4dpharmaplc.com/application/files/1016/4181/5070/4D_pharma_LBPS_DDDD_Corporate_deck_Jan_2022.pdf

To be fair I was more than surprised at your attack, as previously I regarded your posts I presume this reflects the unease at the current situation.

Funny you should pop up - been keeping your head down

PG - I never even suggested anyone should sell. I am invested but now very unsure of the management and their moves to me seem very personal and defensive. I believe I am more that entitled to air my views just as you have done many many times before. Are you on the payroll of someone for gain - seem to post a lot?

I think it is 17 January 2022 here - no results/ big options & further SP depreciation but you are in April! - Whats it going to be in April?

So - who do you think?

If you are happy to bury your head in the sand be my guest.

Unfortunately, the sector does not matter. Shorters only attack companies they think are overvalued and they can gain - the share price depreciation would suggest they have it right here. Clearly management have failed to deliver [If SO thought 4D was primed for success why would he sell - there are multiple ways he could have covered his other posistions] and yet 4D management only response is to award themselves massive options, looks like a very distressed move and we see the SP capitulating further.
There are many brilliant ideas that never surface as novel approaches to problems, there are also many that fail due to bad management and hubris and we might be witnessing one here - under promise and over deliver.

You gotta say that the management have brought this on the whole company - failure to deliver to time, not being upfront with missing deadlines, watching the seller sell with no remedial action and then sticking their piggie noses in the trough for millions of shares whilst everyone else is shafted by dilution. Team played well - NOT

I have no problem with the granting of options in lieu of salary but to be set at such a low strike price and to have no other performance criteria is crass. It has been a dismal 18 months for 4D – outside of a group of PI’s no one has bought (or been sold) the science; No II, No US II (SO is selling down), no further Pharma investment.
Even against the AIM index 4D is 60% down in the last 12mths.

Thank you for the replies - I am hoping that the Angle tech is not being over looked by the NHS / government.